Success for the Oxytrol for Women patch for overactive bladder will depend partly on Merck & Co. Inc. overcoming some of the target population’s likely hesitancy to make behavioral changes linked to its efficacy.
If Merck’s marketing succeeds, the first-in-class OTC switch Oxytrol for Women (transdermal 3.9 mg oxybutynin) could become a blueprint for...